Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Zhendong Chen"'
Autor:
Zhendong Chen, Hongbing Wang, Shukui Qin, Peiguo Cao, Weiguo Su, Sanyuan Sun, Haihui Chen, Jian Li, Jianfeng Zhou, Haijun Zhong, Yanhong Deng, Rubing Han, Lei Yang, Shubin Wang, Weijian Guo, Donghui Chen, Dong Ma, Xiaojun Guo, Rui-Hua Xu, Wei Li, Zhuang Yu, Ying Cheng, Tianshu Liu, Jin Li, Yongqian Shu, Bin Zhang, Jiejun Wang, Hongming Pan, Jianming Xu, Yuxian Bai, Ning Wang, Nong Xu, Changping Wu, Ying Yuan
Publikováno v:
Future Oncology. 17:1339-1350
Background: FRESCO study demonstrated efficacy and safety of fruquintinib in metastatic colorectal cancer patients. Impact of prior targeted therapy (PTT) on efficacy and safety of fruquintinib was evaluated. Materials & methods: In this subgroup ana
Autor:
Zhenggang Ren, Xiao Zhang, Ying Liu, Linna Wang, Jianping Xiong, Hui Li, Jianjun Zou, Xiaojing Zhang, Shukui Qin, Zhendong Chen, Zhiqiang Meng
Publikováno v:
Drug Design, Development and Therapy
Hui Li,1,* Shukui Qin,1,* Ying Liu,2 Zhendong Chen,3 Zhenggang Ren,4 Jianping Xiong,5 Zhiqiang Meng,6 Xiao Zhang,7 Linna Wang,7 Xiaojing Zhang,7 Jianjun Zou7 1Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chin
Autor:
Wei Li, Ying Cheng, Shude Cui, Tao Sun, Masahide Hiraiwa, Peng Yuan, Setsuo Funasaka, Kenichi Saito, Xichun Hu, Xiaojia Wang, Qingyuan Zhang, Binghe Xu, Zhendong Chen, Quchang Ouyang
Publikováno v:
European Journal of Cancer. 112:57-65
Introduction The objective of this study was to evaluate the efficacy and safety of eribulin monotherapy, relative to vinorelbine, in Chinese women with locally recurrent/metastatic breast cancer (MBC). Methods This phase III open-label, randomised,
Autor:
Wangjun Liao, Zhijun Jie, Jianhua Chang, Lejie Cao, Yiping Zhang, Yuping Sun, Min Tao, Jianhua Shi, Zhendong Chen, Jianying Zhou, Weidong Mao, Shenglin Ma, Yu Yao, Chunhong Hu, Sanyuan Sun, Gongyan Chen, Shun Lu, Yong Song, Shukui Qin, Bu-Hai Wang, Yunchao Huang, Weiguo Su, Hongming Pan, Yanping Hu, Jian Fang, Feng Ye, Zhixiong Yang, Mengye Peng, Jianxing He, Li Liang, Yijiang Huang, Zhe Liu, Zhendong Zheng, Jin-Ji Yang, Feng Qiu, Sha Guan, Zhihua Liu, Wei Li, Mingfang Liu, Rui Ma, Dongning Huang, Yuan Chen, Ying Cheng, Xiaoqing Liu, Y. Gong, Junguo Lu, Chong Bai, Li Shan
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 146
Fruquintinib is an orally active kinase inhibitor that selectively targets the vascular endothelial growth factor (VEGF) receptor. A Phase II trial has demonstrated a significant benefit in progression-free survival (PFS) for fruquintinib-treated pat
Autor:
Weijia Fang, Zhiqiang Meng, Xiaoli Chai, Jianping Xiong, Zhendong Chen, Zhenggang Ren, Enxiao Li, Feng Wang, Jianjun Zou, Xiaoyan Lin, Ping Yan, Shukui Qin, Xiaoming Chen, Lin Yang, Xinchen Sun, Linna Wang, Hong Zhu, Yuxian Bai
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an immune checkpoint inhibitor, bu
Autor:
Qingxia Fan, Shukui Qin, Xianbao Zhan, Ming Zeng, Yong Gao, Chen Yun, Kangsheng Gu, Dong Ma, Helong Zhang, Jing Huang, Tao Zhang, Jianhua Chen, Jia Chen, Lei Chen, Tianshu Liu, Zhanhui Miao, Zhendong Chen, Enxiao Li, Zhichao Fu, Jianming Xu, Lu Gan, Jianping Xiong, Ying Yuan, Gang Wu, Zuoxing Niu, Qing Yang, Jianjun Zou, Nong Xu, Li Zhang, Yueyin Pan, Zhiping Li, Yi Ba, Suxia Luo, Jun Wang, Yuxian Bai, H. Lu, Yongqian Shu, Yi Hu, Feng Peng, Xiaodong Jiang, Ying Liu, Yiping Zhang, Lin Shen, Lin Zhao, Lizhu Lin, Wu Zhuang, Wei Ren
Publikováno v:
The Lancet. Oncology. 21(6)
Summary Background Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis and few treatment options after first-line therapy. We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus i
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundEmerging clinical data suggest that an immune checkpoint inhibitor in combination with an antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the combination of camrelizumab with apatinib in pretreated advan
Autor:
T. Chu, Yan Yu, Baohui Han, T. Bai, Helong Zhang, J. Shi, Kai Li, C. Han, M. Bi, Xueji Zhang, Zhendong Chen
Publikováno v:
Annals of Oncology. 30:ii62
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 15, Iss 2, Pp 365-369 (2019)
Aim: We aimed to evaluate the efficacy and safety of apatinib treatment and its impact on the quality of life (QOL) of patients with advanced gastric cancer (GC) who experienced failure with at least two chemotherapeutic regimens. Materials and Metho
Autor:
Y. Xia, Weijia Fang, Xiaoyan Lin, Jianping Xiong, Zhiqiang Meng, Zhenggang Ren, Hong Zhu, J.J. Zou, X.L. Chai, Zhendong Chen, Enxiao Li, Yuxian Bai, S.K. Qin, Ling Yang, X.M. Chen
Publikováno v:
Annals of Oncology. 29:viii719-viii720